NextCure
NXTC
47 hedge funds and large institutions have $36M invested in NextCure in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
136% more capital invested
Capital invested by funds: $15.3M → $36M (+$20.7M)
9% more funds holding
Funds holding: 43 → 47 (+4)
0.84% more ownership
Funds ownership: 3.99% → 4.82% (+0.84%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.76M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$1.95M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$613K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$564K |
| 5 |
Morgan Stanley
New York
|
+$461K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.25M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$464K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$187K |
| 4 |
BlackRock
New York
|
-$185K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
-$73.4K |
NXTC Hedge Fund Activity: Q1 2024 in Review
47 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q1 2024, worth a combined $36M — up 136% from $15.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NXTC positions and 2 closed out — a net gain of 4 holders — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $2.76M. The largest seller was OrbiMed, cutting an estimated $2.25M.
- 47 institutional investors held NextCure (NXTC) as of Q1 2024, up from 43 in Q4 2023.
- Funds reported $36M of NextCure stock for Q1 2024, up 136% quarter-over-quarter.
- 6 funds opened new NextCure positions in Q1 2024 and 2 closed out, a net change of +4 holders.
- The largest NextCure buyer in Q1 2024 was Logos Global Management, an estimated $2.76M added.
- The largest NextCure seller in Q1 2024 was OrbiMed, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2024.